Shots:

• The P-III study involves assessing of SCB-808 vs Enbrel in patients with AS (axSpA) via SC administration
• SCB-808 is being developed in the prefilled syringe formulation which is ready for injection and can be self-administered by the patients- thus overwhelming the current Enbrel biosimilar which are available in lyophilized powder formulation in China
• Clover has new state-of-the-art 35-000m2 cGMP biomanufacturing facility- with initial 2 x 2-000L bioreactor capacity and further expandable to address the unmet medical needs of Chinese patients suffering from autoimmune diseases

Click here to read full press release/ article | Ref: Clover | Image: Signbox